Authors
Latest:
Confronting a Challenging Macroeconomic Environment with InnovationWebinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT
Latest:
5 Myths About BiosimilarsThe introduction of biosimilars has been one of the biggest milestones in autoimmune treatment, but an air of uncertainty still lingers around the true impact of these new players. So what has happened in the market since their arrival?
Latest:
Fuel Growth Through Innovative Talent StrategiesJohn Ebeid outlines talent strategies to reduce an organization's labor costs and increase quality.
Latest:
Global Health: The Need for ConsensusYou can’t make progress without consensus. This holds true for Brexit and for the unparalleled opportunity that the WHO Roadmap report on Access to Medicines and Vaccines presents, writes IFPMA's Greg Perry.
Latest:
Precision Financing of Durable, Potentially Curative TherapiesWhile gene therapies and cellular treatments are a boon for patients, they can be a financial bane for payers. Jane Barlow, Russell Teagarden, and Mark Trusheim outline alternative financing approaches, customizable for each payer’s needs and for each therapy’s characteristics.
Latest:
Engaging with Oncology Providers in a Virtual World*** Live: Thursday, Oct. 29, 2020 at 2pm EDT | 1pm CDT | 11am PDT*** E Get a behind the scenes look into the community oncology provider world through the COVID-19 emergence. Understand provider education needs and preferences and formulate effective strategies to deliver education most adapted to their needs in a virtual world. ***On demand available after final airing until Oct. 29, 2021***
Latest:
When to Utilize Commercial OutsourcingWhen deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Latest:
Op-Ed: Opening the Golden DoorThe talent and tenacity of immigrants can help drive the life sciences industry into the future, if we have the will and the wisdom to encourage it.
Latest:
From PI to Payer to Patient: RWE From the Perspective of Each Key StakeholderHow real-world evidence creates shared value for stakeholders across the healthcare spectrum.
Latest:
Easing the Path to ProfitabilitySteps for startups in tapping non-dilutive financing options.
Latest:
Maximizing the Chance of Launch Success with Orphan DrugsIn preparing to launch a rare-disease medication, it is important to understand the needs in the therapy area and invest strategically to maximize the impact on the unique rare-disease environment.
Latest:
Data As Currency: The Value of Longitudinal Data for PharmaLongitudinal databases can have several advantages for pharma companies in comparison to collecting data from clinical trials alone.
Latest:
Real-Time Information across the Pharma Supply ChainTim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.
Latest:
Closing the Loop: Manufacturing & Regulatory Functions as Data CollaboratorsInformation gaps between manufacturing and regulatory, between ERP and RIM systems, are preventing all the practical and strategic benefits of data-based collaboration, writes Catherine Gambert.
Latest:
What the Purdue Pharma Case Teaches Us About Reputational TornadoesPurdue Pharma and its corporate leadership featured prominently in the media recently as litigation mounts over their sales and marketing of Oxycontin. Nir Kossovsky offers some observations about the lessons this situation provides for all corporate leaders responsible for their companies’ reputations.
Latest:
The Implications of Connected Medical Devices & Digital HealthcareLoetitia Jabri considers the broader implications as healthcare providers embraces new digital connectivity options as part of the Medicine 2.0 era.
Latest:
The Patient Comes First with Outcomes-Based ContractingThe benefits and challenges of outcomes-based contracting.
Latest:
Preparing for the C-SuiteA Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.
Latest:
Are Pharma Marketers Fighting the Last War?Despite being the fastest growing influencers in healthcare, ad campaigns targeted at payers are often an afterthought.
Latest:
Cystic Fibrosis: The Importance of Patient AdvocacyThe importance of patient advocacy in boosting research for cystic fibrosis.
Latest:
Three Tips to Managing Multiple Agency PartnersOutlining three practices that are key to navigating today’s multiplayer agency landscape - and getting more value from each external vendor.
Latest:
The Path to Patient-Focused AccountabilityBenchmark survey assesses the industry’s progress so far in moving from words to action in its approach to patient centricity.
Latest:
Patient Support Programs: Cost, Benefit, and ResourcingWorking group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
